首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1685160

胃肠道粪便检测市场机会、成长动力、产业趋势分析与 2025 - 2034 年预测

GI Stool Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年01月06日 | 出版商:

Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2024 年全球胃肠道粪便检测市场规模达到 6.502 亿美元，预计 2025 年至 2034 年期间的复合年增长率为 7.8%。胃肠道疾病盛行率的不断上升、预防保健意识的不断增强以及诊断技术的不断进步是推动这一增长的主要因素。随着消化健康受到越来越多的关注，医疗保健提供者正在积极将非侵入性且有效的粪便检测方法纳入常规筛检中。粪便诊断工具的准确性、可负担性和可近性的提高进一步支持了这种广泛的应用，使其成为早期疾病检测不可或缺的一部分。

消费者越来越重视主动医疗保健，从而推动了对能够提供可靠结果且不适感最小的基于粪便的诊断的需求。向家庭检测解决方案的转变也促进了市场扩张，使个人可以方便地进行筛检，而无需频繁去医院。此外，政府推动的大肠直肠癌筛检计画和医疗环境中的感染控制措施的措施正在创造有利的监管环境。市场也受益于全球医疗保健基础设施的不断扩张，确保了更广泛地获得先进的诊断解决方案。随着研发力度的加快，人工智慧驱动的分析和基于生物标记的粪便测试等新兴技术正在提高诊断的准确性，进一步加强市场的成长轨迹。

市场范围
起始年份	2024
预测年份	2025-2034
起始值	6.502 亿美元
预测值	14亿美元
复合年增长率	7.8％

2024 年消耗品部分的价值为 4.047 亿美元，涵盖试剂、检测试剂盒和样本采集工具等基本诊断组件。这些物品在确保测试准确且有效率方面发挥着至关重要的作用，因此实验室和医疗机构对它们的需求一直很强烈。一次性消耗品因其能有效降低污染风险并维持严格的感染控制标准而越来越受欢迎。随着医疗保健提供者继续优先考虑精确度和可靠性，对高品质诊断用品的依赖预计会增加。不断扩大的分销网络也改善了这些基本部件的获取，促进了无缝诊断程序。

在各种测试类型中，潜血测试占据市场领先地位，预计到 2034 年将达到 7.126 亿美元，复合年增长率为 8.7%。这些检查对于早期发现大肠直肠癌和胃肠道出血至关重要，可显着改善诊断和治疗结果。它们能够识别粪便样本中隐藏的血迹，这使它们成为国家筛检计画的重要组成部分。潜血检测的经济性和非侵入性鼓励了更多患者参与，支持早期疾病介入。随着医疗保健提供者强调主动疾病管理，对这些测试的需求持续上升。

2024 年，美国胃肠道粪便检测市场价值为 2.737 亿美元，预计到 2034 年复合年增长率为 7.3%。该国先进的医疗保健基础设施和对预防保健的高度重视是推动市场扩张的关键因素。大肠直肠癌筛检的保险覆盖范围的扩大加速了粪便检测解决方案的采用，强调了早期疾病检测的重要性。随着诊断工具的不断进步和对个人化医疗的日益重视，美国市场有望实现持续成长，并透过创新且易于获取的检测解决方案确保改善患者的治疗效果。

产业生态系统分析
产业衝击力
- 成长动力
  - 胃肠道疾病盛行率上升
  - 粪便检测仪器的技术进步
  - 家庭粪便检测试剂盒的普及率不断提高
  - 对胃肠道疾病早期诊断和预防的需求日益增长
- 产业陷阱与挑战
  - 缺乏熟练的专业人员
  - 严格的监理政策
成长潜力分析
2024 年定价分析
报销场景
监管格局
技术格局
差距分析
波特的分析
PESTEL 分析
未来市场趋势
价值链分析

第四章：竞争格局

介绍
公司矩阵分析
公司市占率分析
主要市场参与者的竞争分析
竞争定位矩阵
策略仪表板

第 5 章：市场估计与预测：按产品类型，2021 年至 2034 年

主要趋势
耗材
分析器

第 6 章：市场估计与预测：按测试类型，2021 年至 2034 年

主要趋势
潜血检查
- 免疫FOB凝集试验
- 免疫 FOB ELISA 检测
- 横向流动免疫FOB检测
- 癒创木脂 FOB 粪便测试
细菌检测
粪便生物标记检测
- 肿瘤M2-PK粪便检测
- 转铁蛋白检测
- 其他粪便生物标记测试
虫卵及寄生虫检测
其他测试类型

第 7 章：市场估计与预测：按应用，2021 年至 2034 年

主要趋势
感染
癌症
发炎性肠道疾病
胃食道逆流症（GERD）
其他应用

第 8 章：市场估计与预测：按配销通路，2021 年至 2034 年

主要趋势
实体店面
电子商务

第 9 章：市场估计与预测：依最终用途，2021 年至 2034 年

主要趋势
医院和诊所
诊断中心
家庭护理设置
其他最终用户

第 10 章：市场估计与预测：按地区，2021 年至 2034 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋

第 11 章：公司简介

Abbott Laboratories
danaher
BIO RAD
BIOMRIEUX
CardinalHealth
Cenogenics
CTK BIOTECH
Diasorin
EDI
GENOVA DIAGNOSTICS
meridian BIOSCIENCE
Quest Diagnostics
ScheBo Biotech
SIEMENS

简介目录

Product Code: 5719

The Global GI Stool Testing Market reached USD 650.2 million in 2024 and is projected to expand at a CAGR of 7.8% between 2025 and 2034. The increasing prevalence of gastrointestinal disorders, rising awareness of preventive healthcare, and ongoing advancements in diagnostic technologies are key drivers behind this growth. As digestive health gains more attention, healthcare providers are actively incorporating non-invasive and efficient stool testing methods into routine screenings. This widespread adoption is further supported by the enhanced accuracy, affordability, and accessibility of stool-based diagnostic tools, making them an integral part of early disease detection.

Consumers are increasingly prioritizing proactive healthcare, fueling demand for stool-based diagnostics that provide reliable results with minimal discomfort. The shift towards home-based testing solutions is also contributing to market expansion, allowing individuals to conduct screenings conveniently without frequent hospital visits. Additionally, government initiatives promoting colorectal cancer screening programs and infection control measures in medical environments are creating a favorable regulatory landscape. The market is also benefiting from the continuous expansion of healthcare infrastructure worldwide, ensuring broader accessibility to advanced diagnostic solutions. As research and development efforts accelerate, emerging technologies such as AI-driven analysis and biomarker-based stool tests are enhancing diagnostic accuracy, further strengthening the market's growth trajectory.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$650.2 Million
Forecast Value	$1.4 Billion
CAGR	7.8%

The consumables segment accounted for USD 404.7 million in 2024, encompassing essential diagnostic components such as reagents, test kits, and sample collection tools. These items play a crucial role in ensuring accurate and efficient testing, leading to their consistent demand across laboratories and healthcare facilities. Single-use consumables are becoming increasingly popular due to their effectiveness in reducing contamination risks and maintaining strict infection control standards. As healthcare providers continue prioritizing precision and reliability, the reliance on high-quality diagnostic supplies is expected to grow. Expanding distribution networks are also improving access to these essential components, facilitating seamless diagnostic procedures.

Among various test types, occult blood tests are leading the market, with projections to reach USD 712.6 million by 2034 at a CAGR of 8.7%. These tests are essential for detecting colorectal cancer and gastrointestinal bleeding at an early stage, significantly improving diagnosis and treatment outcomes. Their ability to identify hidden traces of blood in stool samples makes them a critical component of national screening programs. The affordability and non-invasive nature of occult blood tests encourage higher patient participation, supporting early disease intervention. As healthcare providers emphasize proactive disease management, demand for these tests continues to rise.

U.S. GI stool testing market was valued at USD 273.7 million in 2024 and is projected to grow at a CAGR of 7.3% through 2034. The country's advanced healthcare infrastructure and strong focus on preventive care are key factors driving market expansion. Increased insurance coverage for colorectal cancer screenings has accelerated the adoption of stool testing solutions, reinforcing the importance of early disease detection. With continuous advancements in diagnostic tools and a growing emphasis on personalized medicine, the U.S. market is poised for sustained growth, ensuring improved patient outcomes through innovative and accessible testing solutions.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in prevalence of gastrointestinal disorders
  - 3.2.1.2 Technological advancements in stool testing instruments
  - 3.2.1.3 Increasing adoption of at-home stool testing kits
  - 3.2.1.4 Growing demand for early diagnosis and prevention of GI diseases
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Lack of skilled professionals
  - 3.2.2.2 Stringent regulatory policies
3.3 Growth potential analysis
3.4 Pricing analysis, 2024
3.5 Reimbursement scenario
3.6 Regulatory landscape
3.7 Technology landscape
3.8 Gap analysis
3.9 Porter's analysis
3.10 PESTEL analysis
3.11 Future market trends
3.12 Value chain analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

5.1 Key trends
5.2 Consumables
5.3 Analyzers

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 – 2034 ($ Mn)

6.1 Key trends
6.2 Occult blood test
- 6.2.1 Immuno FOB agglutination test
- 6.2.2 Immuno FOB ELISA test
- 6.2.3 Lateral flow immuno FOB test
- 6.2.4 Guaiac FOB stool test
6.3 Bacteria test
6.4 Fecal biomarkers test
- 6.4.1 Tumor M2-PK stool test
- 6.4.2 Transferrin assays
- 6.4.3 Other fecal biomarkers tests
6.5 Ova and parasites test
6.6 Other test types

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

7.1 Key trends
7.2 Infection
7.3 Cancer
7.4 Inflammatory bowel disease
7.5 Gastroesophageal reflux disease (GERD)
7.6 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

8.1 Key trends
8.2 Brick and mortar
8.3 E-commerce

Chapter 9 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

9.1 Key trends
9.2 Hospitals and clinics
9.3 Diagnostic centers
9.4 Homecare settings
9.5 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE